The TriPharm Services facility will address the shortage of qualified parenteral manufacturing options in the US with eight multi-purpose cleanrooms and four isolator filling suites
TriPharm Services, a contract manufacturing and development organisation (CDMO), has announced the commissioning of a new specialised manufacturing operation at its Morrisville facility in North Carolina.
The company said the site has been designed to utilise the latest isolator equipment, as shown in the picture below. As a centre of excellence, the facility specialises in injectable pharmaceutical capabilities, including flexible manufacturing solutions for liquid and lyophilised products.
The Morrisville facility is located at 627 Davis Drive and comprises an area of 32,000 sqft. TriPharm said the site will be equipped with four isolator filling suites and the highest level of control available for Grade A processing of client biologic and small molecule products.
Featuring state-of-the-art equipment, the facility has eight multi-purpose cleanrooms to support manufacturing operations, along with modern, specialised utility systems to scale to client requirements.
Co-founders Patrick Walsh and Eric Evans are behind the new operation and are backed by healthcare private equity firm Ampersand Capital Partners. “TriPharm brings a new option to clients seeking modern, well-equipped manufacturing with an experienced leadership team,” said Walsh. “We are committed to providing a unique, high-quality service to our clients, given the global need for reliable, flexible and scalable manufacturing of injectable pharmaceuticals,” he concluded.
The state-of-the-art equipment and facility are set to be fully operable in the second quarter of 2020.